Announcements Trials
Browse Landscape

Phase

Phase 3 2Phase 2 1

Status

Active not recruiting 2Completed 1

Sponsor Class

INDUSTRY 2NIH 1

Study Type

Interventional 3

Sponsor

Cancer Type

Gynecologic 3Thoracic 1Sarcoma 1Other solid neoplasm 1NET 1Head & Neck 1Gastrointestinal 1Endocrine 1

Conditions

Parkinson Disease 4, Autosomal Dominant Lewy Body 26Carcinoma, Non-Small-Cell Lung 6Melanoma 4Carcinoma, Renal Cell 4Uterine Cervical Neoplasms 3Stomach Neoplasms 3Esophageal Neoplasms 3Endometrial Neoplasms 3Colorectal Neoplasms 3Urinary Bladder Neoplasms 2Triple Negative Breast Neoplasms 2Neoplasms 2Mesothelioma 2Head and Neck Neoplasms 2Cholangiocarcinoma 2Bile Duct Neoplasms 2Vulvar Neoplasms 1Uveal Melanoma 1Urothelial Cancer 1Urologic Neoplasms 1Urethral Neoplasms 1Ureteral Neoplasms 1Thyroid Neoplasms 1Small Cell Lung Carcinoma 1Salivary Gland Neoplasms 1Parotid Neoplasms 1Pancreatic Neoplasms 1Ovarian Neoplasms 1Neuroendocrine Tumors 1Neoplasm Metastasis 1

Interventions

pembrolizumab 3Paclitaxel 3Carboplatin 2ulixertinib 1trastuzumab biosimilar HLX02 1trametinib 1sapanisertib 1sacituzumab govitecan 1relatlimab 1pertuzumab 1palbociclib 1osimertinib 1omipalisib 1olaparib 1lenvatinib 1larotrectinib 1ipatasertib 1erdafitinib 1durvalumab 1defactinib 1dabrafenib 1copanlisib 1capivasertib 1binimetinib 1adavosertib 1X-Rays 1Trastuzumab 1Taxes 1Sunitinib 1Specimen Handling 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Has announcements × Endometrial Neoplasms × pembrolizumab × Clear all
NCT03914612 2026-05-04

Testing the Addition of the Immunotherapy Drug Pembrolizumab to the Usual Chemotherapy Treatment (Paclitaxel and Carboplatin) in Stage III-IV or Recurrent Endometrial Cancer

National Cancer Institute (NCI)

Phase 3 Active not recruiting
813 enrolled 16 charts 1 FDA
GynecologicSarcoma

Carcinosarcoma, Endometrial Neoplasms

NCT03517449 2026-03-19

MK-3475-775

Eisai Inc.

Phase 3 Completed
827 enrolled 34 charts 1 FDA
Gynecologic

Parkinson Disease 4, Autosomal Dominant Lewy Body, Endometrial Neoplasms

NCT02628067 2025-09-22

KEYNOTE 158

Merck Sharp & Dohme LLC

Phase 2 Active not recruiting
1,609 enrolled 4 FDA
EndocrineGastrointestinalGynecologicHead & NeckNETOther solid neoplasmThoracic

Parkinson Disease 4, Autosomal Dominant Lewy Body, Anus Neoplasms, Bile Duct Neoplasms, Biliary Tract Neoplasms, Carcinoid Tumor, Uterine Cervical Neoplasms, Mesothelioma, Parotid Neoplasms, Salivary Gland Neoplasms, Thyroid Neoplasms, Vulvar Neoplasms, Colorectal Neoplasms, Endometrial Neoplasms, Cholangiocarcinoma, Neuroendocrine Tumors, Microsatellite Instability, Small Cell Lung Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡